Literature DB >> 36255629

Analyzing the Effects of HDAC Inhibitors on DNA Damage and Associated Cytotoxicity in Primary Hepatocytes.

Max J Carlsson1, Jörg Fahrer2.   

Abstract

Primary hepatocytes are the gold standard in pharmaco- and toxicokinetic studies during preclinical development of drug candidates. Such cells are a valuable tool to identify potential hepatotoxicity, an important adverse drug reaction. Primary hepatocytes can be obtained not only from wild-type mice but also from genetically engineered knockout mouse strains. Liver perfusion yields murine primary hepatocytes (mpH) with high vitality, expressing an array of metabolic enzymes and transporters that are impaired or even absent in established liver cell lines. Furthermore, mpH display no genetic alterations and are proficient in the DNA damage response pathway. This makes mpH a suitable model to analyze the effects of histone deacetylase inhibitors on DNA damage and cell viability. Here, we report an efficient and fast protocol for the isolation of mpH by liver perfusion. These mpH can be used for downstream applications such as the detection of the DNA damage marker γH2AX by confocal laser scanning microscopy.
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Confocal laser scanning microscopy; DNA damage; Histone deacetylase; Liver perfusion; Primary hepatocytes; γH2AX

Mesh:

Substances:

Year:  2023        PMID: 36255629     DOI: 10.1007/978-1-0716-2788-4_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  17 in total

Review 1.  Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases.

Authors:  Nicholas J Porter; David W Christianson
Journal:  Curr Opin Struct Biol       Date:  2019-02-08       Impact factor: 6.809

Review 2.  Validation of the γH2AX biomarker for genotoxicity assessment: a review.

Authors:  B Kopp; L Khoury; Marc Audebert
Journal:  Arch Toxicol       Date:  2019-07-09       Impact factor: 5.153

Review 3.  Targeting class I histone deacetylases in cancer therapy.

Authors:  Geneviève P Delcuve; Dilshad H Khan; James R Davie
Journal:  Expert Opin Ther Targets       Date:  2012-10-15       Impact factor: 6.902

Review 4.  Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.

Authors:  Mathilde Van Veggel; Elsbeth Westerman; Paul Hamberg
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

5.  Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance.

Authors:  Andrea Krumm; Christina Barckhausen; Pelin Kücük; Karl-Heinz Tomaszowski; Carmen Loquai; Jörg Fahrer; Oliver Holger Krämer; Bernd Kaina; Wynand Paul Roos
Journal:  Cancer Res       Date:  2016-03-15       Impact factor: 12.701

Review 6.  Interstrand Crosslink Repair as a Target for HDAC Inhibition.

Authors:  Teodora Nikolova; Nicole Kiweler; Oliver H Krämer
Journal:  Trends Pharmacol Sci       Date:  2017-07-04       Impact factor: 14.819

Review 7.  Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.

Authors:  Christophe E Redon; Asako J Nakamura; Yong-Wei Zhang; Jiuping Jay Ji; William M Bonner; Robert J Kinders; Ralph E Parchment; James H Doroshow; Yves Pommier
Journal:  Clin Cancer Res       Date:  2010-09-07       Impact factor: 12.531

Review 8.  Panobinostat for the Treatment of Multiple Myeloma.

Authors:  Jacob P Laubach; Philippe Moreau; Jesús F San-Miguel; Paul G Richardson
Journal:  Clin Cancer Res       Date:  2015-09-11       Impact factor: 12.531

Review 9.  Histone deacetylase inhibitors and cell death.

Authors:  Jing Zhang; Qing Zhong
Journal:  Cell Mol Life Sci       Date:  2014-06-05       Impact factor: 9.261

10.  DNA repair by MGMT, but not AAG, causes a threshold in alkylation-induced colorectal carcinogenesis.

Authors:  Jörg Fahrer; Janina Frisch; Georg Nagel; Alexander Kraus; Bastian Dörsam; Adam D Thomas; Sonja Reißig; Ari Waisman; Bernd Kaina
Journal:  Carcinogenesis       Date:  2015-08-04       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.